

Objectives: 1-To assess the efficacy of folic acid supplementation on severity of symptoms and overall functional status of patients
2-To assess the correlation of serum folate levels with symptom severity and overall functional status of patients

Methods: A randomized control trial study was carried out in the inpatient department of a psychiatric tertiary care centre on 40 participants (29 males and 11 females) who were between the ages of 18 – 55 years, met diagnostic criteria for Schizophrenia (ICD 10) and had at least 2 years of illness duration while those with a co-morbid psychiatric illness, medical illness and substance abuse were excluded. The participants were then randomly allocated into two groups (**experimental Group A** which received 5mg folic/day along with anti psychotic drugs and **control Group B** which received only anti psychotic drugs) and followed up for 3 months. Blood sample for measuring serum folate level was obtained from the experimental group at the beginning and at the end of the study period. Scales applied were Positive and Negative Syndrome Scale(PANSS) for symptom severity and Global Assessment of Functioning scale(GAF) for overall functional status.

Results: A significant difference (p value< 0.05) was observed in PANSS scores at the end of the study between experimental group and control group(**table 1**) and also in GAF scores between both the groups after 3 months(**table 2**). At the end of the study period,a strong negative correlation($r= -0.9$) was found between serum folate level and total PANSS score in the experimental group (**figure 1**) while the correlation between GAF score and serum folate level was strongly positive ($r= 0.8$) (**figure 2**).

Table 1

PANSS (3 Month)	Group A(n=20)	Group B (n=20)	P value
Positive	16.8±2.80	22.9±3.37	0.036
Negative	14.3±3.32	15.1±2.61	0.18
General	17.95±2.52	21.85±3.18	0.0001
Total	45.95±3.41	58±3.49	0.00249

Table 2

GAF	Group A(n=20)	Group B (n=20)	P value
0 MONTH	23.25±3.43	22.7±2.90	0.3
3 MONTH	65.75±4.22	44.9±7.09	0.0256

Image:





Image 2:



Conclusions: Our study is among the few to use a randomized controlled study design for assessing the effect of folic acid supplementation on severity of symptoms and global functioning in Schizophrenia, strongly suggesting the use of folic acid as an adjuvant treatment for Schizophrenia.

Disclosure of Interest: None Declared

Schizophrenia and other psychotic disorders 10

EPP1048

Group psychotherapy for patients with first-episode psychosis: Effect on the clinical status and use of resources

P. Herrero Ortega^{1*}, A. Oliva Lozano¹, J. Garde González¹, C. Bayón-Pérez^{1,2,3}, R. Mediavilla^{2,3,4,5}, M. P. Vidal-Villegas^{2,3,4}, B. Rodríguez-Vega^{1,2,3}, S. Cebolla^{1,3}, E. Román^{1,3}, E. V. Pérez Pérez², M. F. Bravo-Ortiz^{1,2,3,5} and O. B. O. AGES-Mind Group¹

¹Department of Psychiatry, Clinical Psychology and Mental Health, La Paz University Hospital; ²School of Medicine, Autonomous University of Madrid (UAM); ³Hospital La Paz Institute for Health Research (IdiPAZ); ⁴La Paz University Hospital Biomedical Research Foundation (FIBHULP) and ⁵Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain

*Corresponding author.

doi: 10.1192/j.eurpsy.2023.1322

Introduction: Psychotic disorders carry several economical, psychological and social consequences, both at individual and community levels. Early intervention programs after first-episode psychosis which combine pharmacological and psychosocial strategies are aimed at reducing symptoms, lowering costs in the use of health and non-health care resources and improving overall functioning. AGES-Mind study is based on manualized psychotherapeutic interventions for people with first-psychosis episodes.

Objectives: The aim of the study was to evaluate the effect of a group psychotherapeutic intervention on the clinical status and use of clinical resources in a sample of patients with first-episode

psychosis at 12 and 24 months after the beginning of the intervention. This cohort will be compared to patients with first-psychosis episodes without group psychotherapeutic intervention.

Methods: Longitudinal, observational, retrospective study on a cohort of N=46 patients with first-episode psychosis within the last 5 years. Two groups of 23 patients each were formed. The participants of one of those groups received group psychotherapy in the context of the AGES-Mind study and the other group received treatment as usual without group intervention. Non-exposed patients were matched by age, gender and time elapsed since first-episode psychosis with those exposed to the intervention. Sociodemographic data, clinical status and use of clinical resources outcome variables were assessed.

Results: No significant differences were found in clinical status and use of resources between participants and non-participants in the psychotherapeutic group intervention after 12 and 24 months.

Conclusions: After controlling for potentially confounding variables as sociodemographic, age and time since first-episode, participating in a group psychotherapeutic program does not seem to improve clinical variables or use of resources. Further studies with larger samples would be necessary to explore other variables, such as symptoms, satisfaction with the intervention or social functioning.

Disclosure of Interest: None Declared

EPP1049

Non-schizophrenic psychotic disorders: Cycloid psychosis. Case report and literature review

P. Herrero Ortega*, J. Garde González, M. A. Morillas Romerosa, A. Oliva Lozano and J. Curto Ramos

Psychiatry, La Paz University Hospital, Madrid, Spain

*Corresponding author.

doi: 10.1192/j.eurpsy.2023.1323

Introduction: Cycloid psychosis is a clinical entity with defining traits which emerged from the Wernicke-Kleist-Leonhard school of psychiatry and has a long history in Europe. Leonhard distinguished three clinical forms: anxiety-happiness, confusion and motility psychosis. It is a condition with high clinical heterogeneity and favorable prognosis.

Objectives: To describe a case of cycloid psychosis and review in literature the heterogeneity of this phenomena and its clinical management.

Methods: Clinical case report and brief review of literature.

Results: 57-year old male with previous diagnosis of paranoid schizophrenia and severe congenital hearing loss. Preserved autonomy and adequate real-life and interpersonal functioning. Along the past few years the patient has presented episodes of a significant clinical global worsening in context of mainly somatic symptoms (intestinal obstruction and volvulus) and minor stressful life events. On this occasion he appears in the emergency room with a new episode of abdominal pain and is admitted to Internal Medicine with presumptive diagnosis of intestinal volvulus. The patient gathered heterogeneous symptoms including disorientation, confusion, generalized tremor, gait disorder, profuse sweating, regressive and oppositional behaviors (refusal to eat or drink liquids) and sudden behavioral oscillations (from agitation to prostration). From the psychic point of view he showed thought blocking,

mutism, significant anxiety, fear of death, delusional prejudice ideas and sensorceptive disturbance which seemed otherwise related to previous sensorial problems. We introduced treatment with Olanzapine 30 mg and after 4 weeks, the patient suddenly showed a significant clinical improvement until the complete remission of the symptoms and restitution of his previous state. In coordination with his regular psychiatrist was proposed the controversial diagnosis of cycloid psychosis. Cycloid psychosis gather a few clinical features which differentiate it from other entities: acute onset, polymorphic symptomatology, global disturbance of psychic life, remitting and recurrent course and favorable prognosis. Regarding its clinical management no controlled studies have been conducted to this date of the treatment of this phenomena. According to literature ECT seems to be an effective treatment as well as low-doses of atypical antipsychotics. Some authors propose pharmacological maintenance treatment with mood stabilizers.

Conclusions: The diagnosis of cycloid psychosis can be useful as well as necessary to describe certain patients with similar clinical features, recurrent course and favorable prognosis. Future studies on pharmacological approach would be useful to ensure the appropriate clinical management of these patients.

Disclosure of Interest: None Declared

EPP1050

The response to unfolded proteins in schizophrenia and bipolar disorder

C. Cachán¹, I. M. Valle², Y. Potes¹, A. González Rubio¹, N. Menéndez Coto¹, D. López Fanjul³, I. Vega Naredo¹, B. Caballero¹, P. Saiz¹, J. Bobes¹, P. García Portilla^{1*} and A. Coto Montes¹

¹University of Oviedo; ²Servicio de Inmunología, Hospital Universitario Central de Asturias (HUCA) and ³Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain

*Corresponding author.

doi: 10.1192/j.eurpsy.2023.1324

Introduction: Schizophrenia (SCH) and bipolar disorder (BD) are severe mental disorders, which have high incidence (Whiteford *et al.* Lancet 2013; 381 1575-86) and are the main causes of disability in young people (WHO 2022; <https://www.who.int/news-room/factsheets/detail/mental-disorders>).

Psychological stress appears in different mental disorders, and this is directly related to oxidative stress (Moller *et al.* Chem Biol Interact. 1996; 102 17-36)(Pupic-Bakrac *et al.* 2020; Psychiatr Danub. 32 412-9). Oxidative stress causes reticulum edoplasmic stress (ER stress) and this produces high levels of misfolded proteins. Defective proteins are degraded by the proteasome, but but when the density of misfolded proteins exceeds the capacity of the proteasome, the Unfolded and Misfolded Protein Response (UPR) is triggered through three main pathways: Inositol-requiring enzyme 1 α (IRE1 α); transcription factor 6 alpha (ATF6 α) and protein kinase RNA-Like ER kinase (PERK), trying to recover normal protein synthesis capacity (Bermejo-Millo *et al.* 2018; Mol Neurobiol. 55 7973-86) (González-Blanco *et al.* 2022; J Cachexia Sarcopenia Muscle 13 919-31).

Objectives: Characterizing ER stress and UPR in SCH and BD.